What a fascinating blog! There is much to digest in GK's blog...

What a fascinating blog!  

There is much to digest in GK's blog about DARRT, so I'll start with the obvious: the reduction in pain and PSA scores means there have been abscopal responses in some patients, with no safety concerns, which Professor Kelly confirmed when he stated that "...we have seen evidence that non-irradiated tumours have responded".

We don't know the degree to which irradiated tumours shrunk, or the precise shrinkage of non-irradiated tumours, but we do not need to know the exact detail in this Phase I trial.  Veyonda appears to have done something that no other drug has achieved in end stage cancer.

Professor Kelly made an unexpected comment about the shortcomings of radiation and checkpoint inhibitors; and that the international pharmaceutical industry is searching for a drug that reactivates innate immune cells within each and every tumour, in a safe and effective manner.  Veyonda, anyone?


I do not intend to respond to the hypocrite Harvett, who clearly is incapable of objective analysis.